Combination Of Tace Plus Rfa In Early And Intermediate Stage Hcc Patients

Background Locoregional therapies are recommended therapies for patients with non-advanced stage hepatocellular carcinoma (HCC). While radiofrequency ablation (RFA) is used for early stage, transarterial chemoembolization (TACE) is the option for intermediate stage disease. The aim of this study was to compare the efficacy and safety of combination of TACE plus RFA with RFA or TACE alone in patients with non-advanced HCC. With new and markedly improved medical treatment options for liver cancer, identifying patients who profit from locoregional therapies is essential.